Astria Therapeutics Inc

NASDAQ:ATXSUnited States

Astria Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing and commercialization of therapies to patients and families affected by rare and niche allergic and immunological diseases. The Company’s lead product candidate is STAR-0215, is a potential monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE. The Company’s on-demand treatment of HAE therapy includes BERINERT, FIRAZYR, KALBITOR and RUCONEST. Its long-term preventative treatment of HAE therapy includes CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO.

Contact Information

Headquarters

75 State Street, Suite 1400BOSTON, MA, United States 02109

Phone

617-349-1971

Fax

617-273-2637

Executives

Independent Chairman of the Board

Kenneth Bate

President, Chief Executive Officer, Co-Founder, Principal Financial Officer, Director

Jill Milne

Chief Financial Officer

Noah Clauser

Chief Scientific Officer

Andrew Nichols

Chief Legal Officer

Benjamin Harshbarger